Pilot Study Evaluating Sulforaphane in Atypical Nevi-Precursor Lesions
| Status: | Completed |
|---|---|
| Conditions: | Skin Cancer, Dermatology |
| Therapuetic Areas: | Dermatology / Plastic Surgery, Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 1/11/2018 |
| Start Date: | August 2012 |
| End Date: | April 2016 |
A Pilot Study Evaluation of Sulforaphane in Atypical Nevi--Precursor Lesions: Assessment of STAT1 and STAT3 Risk Markers of Melanoma
This is a pilot study to see if oral administration of freeze dried, powdered broccoli
sprouts have any effect on whether moles end up becoming melanoma.
sprouts have any effect on whether moles end up becoming melanoma.
This study is designed as a pilot evaluation of sulforaphane as a candidate natural
nutritional chemopreventive agent able to modulate key steps in melanoma progression and the
expression of STAT proteins in melanocytic and stromal elements of atypical nevi, which are
precursor lesions and risk markers of melanoma. Eighteen individuals in total will receive
oral broccoli sprout extract rich in sulforaphane (BSE-SFN) standardized for 3 different
concentrations of actual sulforaphane content which will be utilized in our study. Three
groups of six patients will be randomly assigned to receive oral BSE-SFN at SFN dosages of 50
µmol, 100 µmol, or 200 µmol daily. Due to the established safety of SFN at all of the
proposed dosage levels, there is no plan to complete a lower dosage level prior to escalating
to the next higher dosage level; i.e., subjects will be randomized across all of the proposed
SFN dosage levels. However, the safety of BSE-SFN administration will continue to be
evaluated through laboratory studies (CBC, chemistry) performed before and following 28 days
of administration.
nutritional chemopreventive agent able to modulate key steps in melanoma progression and the
expression of STAT proteins in melanocytic and stromal elements of atypical nevi, which are
precursor lesions and risk markers of melanoma. Eighteen individuals in total will receive
oral broccoli sprout extract rich in sulforaphane (BSE-SFN) standardized for 3 different
concentrations of actual sulforaphane content which will be utilized in our study. Three
groups of six patients will be randomly assigned to receive oral BSE-SFN at SFN dosages of 50
µmol, 100 µmol, or 200 µmol daily. Due to the established safety of SFN at all of the
proposed dosage levels, there is no plan to complete a lower dosage level prior to escalating
to the next higher dosage level; i.e., subjects will be randomized across all of the proposed
SFN dosage levels. However, the safety of BSE-SFN administration will continue to be
evaluated through laboratory studies (CBC, chemistry) performed before and following 28 days
of administration.
Inclusion Criteria:
- Subjects must have at least two atypical nevi of ≥ 4 mm diameter and prior diagnosis
of melanoma.
- Subjects must be ≥ age 18.
- Subjects must not have received any form of systemic antineoplastic treatment for
melanoma within the last year from day 1.
- Subjects should not have known allergies to cruciferous vegetables.
- Subjects must agree to abstain from dietary sources of glucosinolates and
isothiocyanates beginning three days prior to study and throughout duration of the
active study (28 days). Participants will be asked to keep a food diary. A list of
food and supplements to abstain from is provided in Appendix A. Patients will be asked
to record instances of accidental ingestion of these foods, with patients being
removed from the study if this occurs 7 or more times.
- Female subjects must not be pregnant or breast feeding within 6 months prior to and
during course of study.
- CBC including diff & platelets - without clinically significant abnormalities
- CMP (Na, K, Cl, CO2, glucose, BUN, creatinine, calcium, total protein, albumin, AST,
ALT, ALK phos, total bilirubin) - within 2x ULN
Exclusion Criteria:
We found this trial at
1
site
Click here to add this to my saved trials
